US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

63.63

+0.07440.12%

Post-market: 63.630.00000.00%16:10 EDT

Volume:9K

Turnover:589.16K

Market Cap:274.88M

PE:20.81

High:63.63

Open:63.27

Low:62.99

Close:63.55

52wk High:64.10

52wk Low:39.10

Shares:4.32M

Float Shares:4.32M

Volume Ratio:0.27

T/O Rate:0.22%

Dividend:1.53

Dividend Rate:2.40%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall

MT Newswires Live

Guardant Health to appeal federal district court judgment in TwinStrand case

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":63.629,"timestamp":1787774400000,"preClose":63.5546,"halted":0,"volume":9295,"hourTrading":{"tag":"盘后","latestPrice":63.629,"preClose":63.629,"latestTime":"16:10 EDT","volume":19,"amount":1212.31647,"timestamp":1787775005418,"change":0,"changeRate":0,"amplitude":0.015834},"delay":0,"changeRate":0.0011706469712656068,"floatShares":4320000,"shares":4320000,"eps":3.057033,"marketStatus":"Post-Mkt","change":0.0744,"latestTime":"08-26 19:49:57 EDT","open":63.27,"high":63.629,"low":62.985,"amount":589164,"amplitude":0.010133,"askPrice":64.27,"askSize":4700,"bidPrice":62.89,"bidSize":4800,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":63.5546,"sharesOutstanding":2480000,"nav":62.38373,"aum":275112249.3,"dividendRate":0.023972,"bidAskSpread":0.002285,"preHourTrading":{"tag":"盘前","latestPrice":63.5546,"preClose":63.5546,"latestTime":"07:01 EDT","volume":1,"amount":63.5546,"timestamp":1787742068433,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":63.629,"preClose":63.629,"latestTime":"16:10 EDT","volume":19,"amount":1212.31647,"timestamp":1787775005418,"change":0,"changeRate":0,"amplitude":0.015834},"volumeRatio":0.26737,"impliedVol":0.0861,"impliedVolPercentile":0.2629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4320000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.26737,"shares":4320000,"dividePrice":1.5253,"high":63.629,"amplitude":0.010133,"preClose":63.5546,"low":62.985,"week52Low":39.1,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":63.629,"committee":0.010526,"eps":3.057033,"divideRate":0.023972,"volume":9295,"delay":0,"ttmEps":3.057033,"open":63.27,"prevYearClose":49.701,"prevWeekClose":62.9761,"prevMonthClose":58.0963,"prevQuarterClose":59.76,"fiveDayClose":64.0724,"twentyDayClose":57.08,"sixtyDayClose":50.8485},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662574411","title":"Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2662574411","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662574411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:15","pubTimestamp":1787775315,"startTime":"0","endTime":"0","summary":"• BrightSpring reported strong second-quarter revenue and raised its full-year guidance.\n• Wall Street analysts maintained buy ratings with an average price target of $78.97.\n• Annual revenue reached $12.91 billion with a net profit of $190.67 million.","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262133901-market-movers-btsg-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","PSCH","LU2468319806.SGD","BTSG","BK4196","LU2324357040.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749358","title":"Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749358","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662749358?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:20","pubTimestamp":1787768430,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.Price: 215.95, Change: +4.57, Percent Change: +2.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","BBH","LU0889565916.HKD","LU0109394709.USD","IE0009355771.USD","PTH","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE0009354923.USD","IE00BFTCPJ56.SGD","RVMD","IDNA","IE00BJT1NW94.SGD","BK4139","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746776","title":"Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746776","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746776?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:02","pubTimestamp":1787767375,"startTime":"0","endTime":"0","summary":"Price: 215.72, Change: +4.34, Percent Change: +2.05","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBH","IE0009355771.USD","IE00BFTCPJ56.SGD","PTH","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","CANC","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0889565916.HKD","IDNA","RVMD","IE0002141913.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662462057","title":"Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662462057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662462057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:56","pubTimestamp":1787766961,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","CANC","IE0009354923.USD","IDNA","LU0320765992.SGD","BK4139","BBH","RVMD","IE00B4R5TH58.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746411","title":"Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746411","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766356,"startTime":"0","endTime":"0","summary":"Revolution Medicines posts investor presentation on RASONQUE FDA approvalRevolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4qMXCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE0009354923.USD","IE00BJT1NW94.SGD","RVMD","CANC","PTH","LU0320765992.SGD","IDNA","BK4139","IE0002141913.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4588","XLVX","PSCH","IEIH","NVIB","TECB","BK4139","PTH","MRNY","IE00B4R5TH58.HKD","CANC","BBH","BMED","IYH","LFSC","PINK","LABU","SYNB","MRNX","IE00BFTCPJ56.SGD","LU0889565916.HKD","LU0109394709.USD","IE0009354923.USD","GDOC","IDNA","IE00BJT1NW94.SGD","RVMD","RSPH","IE00BJJMRZ35.SGD","TBXU","IE0002141913.USD","BK4585","LU0320765992.SGD","MEDI","BBP","FRTY","IE00B2B36J28.USD","IBB","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","LU0320765992.SGD","IDNA","FRTY","TECB","XLVX","MRNX","BK4585","IBB","RVMD","MEDI","BK4139","IE00B4R5TH58.HKD","IEIH","NVIB","PTH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","PSCH","LU0109394709.USD","LABU","MRNY","PINK","IE0002141913.USD","TBXU","BK4588","IE0009355771.USD","BBH","GNMX","BMED","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00B2B36J28.USD","LU0889565916.HKD","GDOC","LFSC","RSPH","CANC","IYH","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745207","title":"Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745207?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BBH","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","IE0009355771.USD","BK4139","IDNA","CANC","IE00BJJMRZ35.SGD","IE0009354923.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","RVMD","IE0002141913.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662452007","title":"U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662452007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662452007?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","IE00BFTCPJ56.SGD","RVMD","CANC","IE0002141913.USD","IDNA","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BBH","IE0009355771.USD","LU0109394709.USD","IE0009354923.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759746","title":"U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759746","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763540,"startTime":"0","endTime":"0","summary":"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent syste","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ITT","BK4613","BK4141","SRET","TTDU","BK4585","LU2487616109.SGD","ONX","LU0109394709.USD","ON","IE00BJJMRZ35.SGD","L","IE00B2B36J28.USD","LU0724618433.USD","LU0320765992.SGD","TTD","PTH","PFS","IE0002141913.USD","IE00BZ199S13.USD","LU1861220033.SGD","IE00B4R5TH58.HKD","IDNA","LU0124384867.USD","LU1978683503.SGD","LU2360107325.USD","LU0053671581.USD","IE0009355771.USD","BK4225","BK4023","BK4605","HR","BBH","IE00BD6J9T35.USD","BK4512","LABU","LU1720051108.HKD","LU0210528500.USD","RVMD","BK4009","LU0889565916.HKD","LU1720051017.SGD","ONG","EMA","LU1861219969.SGD","CANC","IE0009354923.USD","LU1854103824.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163553180","title":"Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption","url":"https://stock-news.laohu8.com/highlight/detail?id=1163553180","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163553180?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:30","pubTimestamp":1787758250,"startTime":"0","endTime":"0","summary":"Boston Scientific disclosed in a Wednesday filing with the U.S. Securities and Exchange Commission (SEC) that it has been struck by a cyberattack, impacting its business operations. The incident is...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2244417387.USD","LU2112291526.USD","BK1574","BK4588","MEDX","LU0823416689.USD","LU1791710582.SGD","RSPH","HAKY","LU1718418525.SGD","IEIH","SG9999001176.USD","WCBR","IE00B2B36J28.USD","LU1989764664.SGD","LU2324357040.USD","SGXZ57979304.SGD","PTH","BK4581","LU0950375773.USD","LU2491050071.SGD","LU2362540622.SGD","BK1100","IE0002141913.USD","LU1804176565.USD","LU0345769631.USD","LU2357305700.SGD","LU0882574055.USD","LU0238689110.USD","LU1291159041.SGD","HART","LU1720051108.HKD","LU0011850046.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4504","LU0353189763.USD","LU2491049909.HKD","LU0077335932.USD","LU0251132253.USD","LU0345769128.USD","LU0138981039.USD","LNGR","LU0187121727.USD","LU1989764748.USD","SG9999001176.SGD","LU0114720955.EUR","09996","LU0225283273.USD","LU1989772840.SGD","LU0528227936.USD","IE00BJT1NW94.SGD","LU1720051017.SGD","SPAM","LU1057294990.SGD","LU1791710400.SGD","BK4082","LU1061106388.HKD","GDOC","LU0353189680.USD","LU0823417653.USD","LU1548497426.USD","LU2506952170.USD","LU1983299246.USD","LU0823417737.USD","LGHT","BSX","LU0122379950.USD","LU2506952097.USD","UCYB","LU1153585028.USD","LU2265009873.SGD","LU2506951958.HKD","LU1989772923.USD","LU1989771016.USD","BK4585","LU2362541273.HKD","LU2362541513.USD","LU0432979614.USD","MDEV","LU2491050154.USD","LU0266013472.USD","SG9999013999.USD","IE0009355771.USD","LU0048584097.USD","LU2506951875.HKD","LU2087625088.SGD","AGNG","159883","IE00B4R5TH58.HKD","LU1023059063.AUD","BK1583","LU1366192091.USD","LU2242649171.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748785","title":"FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748785?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:18","pubTimestamp":1787757480,"startTime":"0","endTime":"0","summary":"For four decades, cancer researchers fought to disable a stubborn mutation that made pancreatic cancer a death sentence-to little avail.Now, doctors have a medicine that targets the mutation. The Food","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6027","IE00B2B36J28.USD","IE0009354923.USD","RDR.SI","BK6515","BK4139","RVMD","BK4585","BBH","IE00B4R5TH58.HKD","IE0002141913.USD","IDNA","BK4588","PTH","LU0109394709.USD","LU0889565916.HKD","CANC","LABU","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748478","title":"Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748478","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748478?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:12","pubTimestamp":1787757130,"startTime":"0","endTime":"0","summary":"Roivant says JAMA Dermatology publishes Phase 3 VALOR data showing brepocitinib improves dermatomyositis skin outcomesRoivant reported a JAMA Dermatology publication of skin-focused Phase 3 VALOR resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4G7BRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","IE00BQXX3D17.EUR","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4007","SG9999014039.USD","BK4588","IE00BGHQF748.EUR","BK4139","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","ROIV","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","BCDF","PTH","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662441748","title":"Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662441748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662441748?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:11","pubTimestamp":1787757107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA2RQXQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662107077","title":"US FDA Approves Revolution Medicines' Pancreatic Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662107077","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662107077?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:43","pubTimestamp":1787755405,"startTime":"0","endTime":"0","summary":"US FDA approves Revolution Medicines' pancreatic cancer drugAug 26 (Reuters)-The U.S. Food and Drug Administration approved Revolution Medicines'RVMD.Otargeted drug for metastatic pancreatic cancer, the regulator said on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N16Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","IE00BJT1NW94.SGD","IDNA","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0009354923.USD","PTH","LU0320765992.SGD","IE00BJJMRZ35.SGD","BK4139","BBH","IE00B4R5TH58.HKD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662102887","title":"FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662102887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662102887?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:38","pubTimestamp":1787755107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B2B36J28.USD","LU0889565916.HKD","RVMD","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","BBH","IE00BFTCPJ56.SGD","IDNA","CANC","LU0109394709.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662502718","title":"Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662502718","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662502718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:52","pubTimestamp":1787741522,"startTime":"0","endTime":"0","summary":"Revolution Medicines CEO Mark A. Goldsmith reports disposal of common shares worth $16.87 millionRevolution Medicines CEO Mark A. Goldsmith exercised stock options for 80,000 shares at USD 4.73 on Aug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5Nrx4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PTH","LU0320765992.SGD","IDNA","IE00B4R5TH58.HKD","IE0009354923.USD","IE00BJT1NW94.SGD","CANC","IE0002141913.USD","BK4139","BBH","IE00BJJMRZ35.SGD","LU0889565916.HKD","RVMD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020952","title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020952","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662020952?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:22","pubTimestamp":1787606549,"startTime":"0","endTime":"0","summary":"Guardant Health Co-CEO AmirAli Talasaz disposes of USD 6.35 million in common sharesGuardant Health Co-CEO AmirAli Talasaz sold 37,500 common shares on Aug. 21, 2026 through the Talasaz Family Foundat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9NSL6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4588","EKG","LFSC","PTH","GH","GNOM","HELX","LU0889565916.HKD","GNMX","BK4535","FFOX","LU0109394709.USD","LU0320765992.SGD","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205974","title":"Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205974?lang=en_us&edition=fundamental","pubTime":"2026-08-25 03:41","pubTimestamp":1787600471,"startTime":"0","endTime":"0","summary":"Guardant Health  said Monday it will appeal the final judgment of a Delaware district court related to a patent infringement dispute with TwinStrand Biosciences and University of Washington.The company said execution of the court's final decision and collection of potential royalties are on hold, pending the appeal.The potential royalties do not apply to the company's current versions of Guardant Reveal and Shield, which feature updated technology. Additionally, the company has made design improvements to Guardant360 that would exclude the impact of potential ongoing royalties.The patents have also been preliminarily invalidated in separate challenges before the US Patent and Trademark Office, the company added.Shares fell around 3.5% in late afternoon trading.Price: 164.62, Change: -6.07, Percent Change: -3.56","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4551","BK4588","EKG","LFSC","PTH","GH","GNOM","HELX","LU0889565916.HKD","GNMX","BK4535","FFOX","LU0109394709.USD","LU0320765992.SGD","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662030912","title":"Guardant Health to appeal federal district court judgment in TwinStrand case","url":"https://stock-news.laohu8.com/highlight/detail?id=2662030912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662030912?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:55","pubTimestamp":1787597714,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","LU0109394709.USD","FFOX","GH","HELX","BK4588","BK4535","GNOM","BK4551","LU0889565916.HKD","LU0320765992.SGD","LFSC","GDOC","EKG","BK4585","GNMX","BK4196"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}